Cogent Biosciences Inc
COGT
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.3B
Close$
$0.37
98.8% downside
Current Fair Value
98.8% downsideOvervalued by 98.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.30 Billion |
|---|---|
| Enterprise Value | $5.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.04 |
| Beta | 0.32 |
| Outstanding Shares | 171,005,468 |
Return
| Return on Equity | -70.85% |
|---|---|
| Return on Assets | -45.20% |
| Return on Invested Capital | -50.18% |
Valuation & Multiples
| P/E Ratio | -13.42 |
|---|---|
| PEG | -43.13 |
| Price to Sales | - |
| Price to Book Ratio | 9.84 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.78 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$1,000
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$750,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 28.28% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 289.53% |
|---|---|
| Total Invested | $61,382▼ 100.00% |
| Investors Holding | 6▼ 330.00% |
ESG Score
No data
About Cogent Biosciences Inc
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently ...